Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with adhd / Sheut-Ling Lam en The American Journal of Psychiatry, Año 2022 - Vol. 179 - No. 12 (Diciembre)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 947-958 Título : Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with adhd Tipo de documento: texto impreso Autores: Sheut-Ling Lam, Autor ; Marion Criaud, Autor ; Steve Lukito, Autor Fecha de publicación: 2023 Artículo en la página: pp. 947-958 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastornos del neurodesarrollo, Trastorno por déficit de atención e hiperactividad (TDAH), Neuroimagen, Neurorretroalimentación Resumen: Functional MRI neurofeedback (fMRI-NF) could potentially be a novel, safe nonpharmacological treatment for attention deficit hyperactivity disorder (ADHD). A proof-of-concept randomized controlled trial of fMRI-NF of the right inferior frontal cortex (rIFC), compared to an active control condition, showed promising improvement of ADHD symptoms (albeit in both groups) and in brain function. However, comparison with a placebo condition in a larger trial is required to test efficacy. Link: ./index.php?lvl=notice_display&id=29784 [artículo] Double-blind, sham-controlled randomized trial testing the efficacy of fmri neurofeedback on clinical and cognitive measures in children with adhd [texto impreso] / Sheut-Ling Lam, Autor ; Marion Criaud, Autor ; Steve Lukito, Autor . - 2023 . - pp. 947-958. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2022 - Vol. 179 - No. 12 (Diciembre) . - pp. 947-958 Palabras clave: Trastornos del neurodesarrollo, Trastorno por déficit de atención e hiperactividad (TDAH), Neuroimagen, Neurorretroalimentación Resumen: Functional MRI neurofeedback (fMRI-NF) could potentially be a novel, safe nonpharmacological treatment for attention deficit hyperactivity disorder (ADHD). A proof-of-concept randomized controlled trial of fMRI-NF of the right inferior frontal cortex (rIFC), compared to an active control condition, showed promising improvement of ADHD symptoms (albeit in both groups) and in brain function. However, comparison with a placebo condition in a larger trial is required to test efficacy. Link: ./index.php?lvl=notice_display&id=29784

---

1 (1 - 1 / 1)